Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE3
INTERVENTIONAL
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Acute Burn ResUscitation Multicenter Prospective Trial
NCT04356859
Albumin Use in Burn Patients
NCT00609414
A Study to Evaluate the Efficacy of Cytal® Burn Matrix in the Management of Partial-Thickness Burns to the Hand
NCT03598023
A Randomized Comparison Study of Aquacel Ag and Glucan II as Donor Site Dressings
NCT00581217
Non-cultured Autologous Keratinocyte Suspension Versus Traditional Split Skin Graft for Burn Wounds Treatment
NCT03675568
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Askina Calgitrol Paste
Askina Calgitrol Paste
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Askina Calgitrol Paste
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* III degree thermal burns from 2-30% TBSA as determined by the Rule of Nines
* Patients who underwent initial treatment within 24 hours after the injury at the latest
* Patients who underwent initial treatment directly at the Burn Centre of FNKV or the initial treatment was in accordance with the standard of care of the Centre
* All patients will have been hospitalised
* Patients who are capable of giving signing informed consent and have done so.
Exclusion Criteria
* Patients with already infected wounds
* Patients taking systemic antibiotics on admission
* Patients pregnant or lactating
* Patients who fall into "vulnerable population" group with respect to informed consent or who are not capable of giving informed consent
* Patients who used or were treated with silver products for other reasons than treatment of the acute burn in the last 3 months
* Patients whose other burn wounds are being treated with silver products.
* Patients receiving renal dialysis
* Known allergy or sensitivity to any of the ingredients in Askina® Calgitrol® Paste.
* Simultaneous participation in another interventional clinical trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BBraun Medical SAS
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OPM-G-H-1204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.